You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR SURFAXIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SURFAXIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00215540 ↗ SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Terminated Windtree Therapeutics Phase 2 2005-02-01 SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS).
NCT00215553 ↗ KL₄Surfactant Treatment in Patients With ARDS Terminated Windtree Therapeutics Phase 2 2001-05-01 Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
NCT00807235 ↗ Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants Terminated Windtree Therapeutics Phase 2 2005-01-01 To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
NCT04389671 ↗ The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) Recruiting Windtree Therapeutics Phase 2 2020-11-02 This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SURFAXIN

Condition Name

Condition Name for SURFAXIN
Intervention Trials
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) 1
Acute Respiratory Distress Syndrome 1
Bronchopulmonary Dysplasia 1
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SURFAXIN
Intervention Trials
Respiratory Distress Syndrome, Newborn 4
Respiratory Distress Syndrome, Adult 4
Respiratory Distress Syndrome 4
Premature Birth 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SURFAXIN

Trials by Country

Trials by Country for SURFAXIN
Location Trials
United States 8
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SURFAXIN
Location Trials
California 2
Pennsylvania 2
North Carolina 1
Massachusetts 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SURFAXIN

Clinical Trial Phase

Clinical Trial Phase for SURFAXIN
Clinical Trial Phase Trials
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SURFAXIN
Clinical Trial Phase Trials
Terminated 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SURFAXIN

Sponsor Name

Sponsor Name for SURFAXIN
Sponsor Trials
Windtree Therapeutics 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SURFAXIN
Sponsor Trials
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.